Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.2 USD | -3.08% | -2.27% | -30.82% |
04/06 | Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | CI |
15/05 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.82% | 17.86M | |
+16.59% | 44.44B | |
+41.02% | 39.84B | |
-10.62% | 37.68B | |
+29.92% | 31.46B | |
-9.23% | 27.02B | |
+12.34% | 26.29B | |
+41.53% | 13.8B | |
+31.49% | 12.46B | |
-7.40% | 11.26B |
- Stock Market
- Equities
- LUMO Stock
- News Lumos Pharma, Inc.
- Transcript : NewLink Genetics Corporation Presents at 36th Annual J.P. Morgan Healthcare Conference, Jan-11-2018 11